Literature DB >> 18207572

Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.

Phillip Müller1, Nava Asher, Maya Heled, Sara Bar Cohen, Angela Risch, Deborah Rund.   

Abstract

Drug metabolism/disposition and transporter genes may influence predisposition or prognosis of AML (acute myeloid leukemia) patients. We analyzed polymorphisms in 3 transporters and 4 drug metabolism genes in 293 Israeli individuals (112 AML patients and 181 controls). We analyzed: ABCC3 (MRP3) C-211T; ABCG2 (BCRP) C421A; CNT1 (SLC28A1) G565A and NAT1, NAT2, and GSTT1 and GSTM1 null alleles for influence on predisposition, as well as treatment response and survival. We found that the ABCC3 C-211T polymorphism and GSTM1 null genotype have adverse prognostic significance in AML. None of the other polymorphisms studied were found to influence either predisposition or prognosis in Israeli AML patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18207572     DOI： 10.1016/j.leukres.2007.10.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  15 in total

1.  Population-specific GSTM1 copy number variation.

Authors:  R Stephanie Huang; Peixian Chen; Steve Wisel; Shiwei Duan; Wei Zhang; Edwin H Cook; Soma Das; Nancy J Cox; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2008-10-23       Impact factor: 6.150

Review 2.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

3.  Investigation of the functional single-nucleotide polymorphisms in the BCRP transporter and susceptibility to colorectal cancer.

Authors:  Fatih M Sari; Hakan T Yanar; Gul Ozhan
Journal:  Biomed Rep       Date:  2014-11-11

4.  Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.

Authors:  Jesse D Troy; Joel L Weissfeld; Brenda Diergaarde; Ada O Youk; Shama C Buch; Marjorie Romkes; Jennifer R Grandis
Journal:  Cancer Epidemiol       Date:  2013-03-21       Impact factor: 2.984

5.  Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Hana Salimizand; Sabrieh Amini; Mohammad Abdi; Bayazid Ghaderi; Namam-Ali Azadi
Journal:  Tumour Biol       Date:  2015-08-07

6.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature.

Authors:  Pin Chen; Lin Zhao; Peng Zou; Haitao Xu; Ailin Lu; Peng Zhao
Journal:  BMC Cancer       Date:  2012-09-01       Impact factor: 4.430

8.  Copy number polymorphisms and anticancer pharmacogenomics.

Authors:  Eric R Gamazon; R Stephanie Huang; M Eileen Dolan; Nancy J Cox
Journal:  Genome Biol       Date:  2011-05-25       Impact factor: 13.583

Review 9.  Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?

Authors:  Lara E Sucheston-Campbell; Alyssa Clay; Philip L McCarthy; Qianqian Zhu; Leah Preus; Marcelo Pasquini; Kenan Onel; Theresa Hahn
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 10.  The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.

Authors:  Jose J G Marin; Maria J Monte; Alba G Blazquez; Rocio I R Macias; Maria A Serrano; Oscar Briz
Journal:  Acta Pharmacol Sin       Date:  2013-12-09       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.